⌘K
t
Avacta Group plc announced on April 29, 2025, that non-executive director Dr. Trevor Nicholls is retiring from the Board. His retirement is effective from April 30, 2025, after serving since his appointment in 2013. Mark Goldberg will take over as Chair of the Remuneration Committee.
| Date | 29 Apr 2025 |
| Time | 07:00:12 |
| Category | Board changes |
| ID | 5158G |
Avacta Group plc
("Avacta" or the "Group" or the "Company")
Board change
LONDON and PHILADELPHIA - April 29, 2025 - Avacta Therapeutics (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs, today announces that Dr. Trevor Nicholls, one of the Group's non-executive directors, is retiring from the Board with effect from April 30, 2025.
Mark Goldberg will take over as the Board's Chair of the Remuneration Committee
Shaun Chilton, non-executive Chairman commented:
"On behalf of the Avacta Board, I would like to thank Trevor for his valued contribution and dedication to the Company since his appointment in 2013 and wish him all the best for the future.
"As Avacta transitions to a pure-play biotechnology company, we have initiated the process of appointing an independent non-executive director with relevant international commercial experience and expertise. A further announcement will be made in due course."
For further information from Avacta Group plc, please contact:
|
Avacta Group plc Michael Vinegrad, Group Communications Director |
|
|
|
|
|
Peel Hunt (Nomad and Joint Broker) James Steel / Chris Golden
|
|
|
Panmure Liberum (Joint Broker) Emma Earl / Will Goode / Mark Rogers
ICR Healthcare Mary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert |
www.panmureliberum.com
|
|
Investor Contact Renee Leck THRUST Strategic Communications
|
|
|
Media Contact Carly Scaduto Carly Scaduto Consulting |
|
About Avacta - www.avacta.com
Avacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION® platform. pre|CISION® is a proprietary warhead delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate highly potent warheads in the tumor microenvironment while sparing normal tissues. Our innovative pipeline consists of pre|CISION® peptide drug conjugates (PDC) or Affimer® drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates.